Scholars Central

Conference abstractPublished 2 Oct 2017

Designed peptidomimetics disrupt protein-protein interactions mediating amyloid protein aggregation

Authors: Sandrine Ongeri

UniversitÃ?© Paris Saclay, France

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Amyloid fibrils are self-assembled insoluble aggregates that constitute the hallmark of more than 20 serious human amyloidosis diseases, such as AlzheimerâÂ?Â?s disease (AD) and type II diabetes. Current drugs have failed to slow the progression of AD, which affects more than 35 million people worldwide. How drug candidates that reduce fibril formation act on the most neurotoxic oligomeric forms of amyloid peptide AÃ?²1-42 is far from being established. We report herein the capacity of two new classes of peptidomimetics to inhibit both AÃ?²1-42 early oligomerization and fibrillization: 1- sugar-based peptidomimetic analogs having physicochemical properties for drug-likeness[1]; 2- Ã?²-hairpin mimics[2]. A wide range of bioand physico-chemical techniques, such as Thioflavin-T fluorescence spectroscopy, transmission electronic microscopy, a new developped capillary electrophoresis method[3], electrospray differential mobility analysis[4], nuclear magnetic resonance, and surface plasmon resonance, was used in order to identify the molecular mechanisms by which these new series of molecules can delay the aggregation of AÃ?²1-42. This is the first example of small molecules that preserves the non toxic monomeric species of AÃ?²1-42. Some compounds suppress totally the toxicity of AÃ?²1-42 towards SH-SY5Y human neuroblastoma cells, even at sub-stoichiometric concentrations. This protective effect is much more significant than that observed with molecules that have undergone clinical trials which reduce AÃ?²1-42 toxicity only at stoichiometric or higher concentrations. Preliminary results on the inhibition of IAPP aggregation involved in type II diabetes will be also presented. [1] a) B. Dorgeret, L. KhemtÃ?©mourian, I. Correia, J-L Soulier, O. Lequin, S. Ongeri Eur. J. Med. Chem. 2011, 46, 5959. (b) J. Kaffy, D. Brinet, J-L Soulier, L. KhemtÃ?©mourian, O. Lequin, M. Taverna, B. Crousse, S. Ongeri, Eur. J. Med. Chem. 2014, 86, 752; c) J. Kaffy, D. Brinet, J-L Soulier, I. Correia, N. Tonali, K. F. Fera, Y. Iacone, A. R. F. Hoffmann, L. Khemtemourian, B. Crousse, M. Taylor, D. Allsop, M. Taverna, O. Lequin, S. Ongeri, J. Med. Chem. 2016, 59, 2025. [2] a) S. Pellegrino, N. Tonali, E. Erba, J. Kaffy, M. Taverna, A. Contini, M. Taylor, D. Allsop, M. L. Gelmi, S. Ongeri Chemical Science, 2017, 8, 1295; b), L. Vahdati, J. Kaffy; D. Brinet; G. Bernadat, I. Correia, S. Panzeri, R. Fanelli, O. Lequin, M. Taverna, S. Ongeri, U. Piarulli. Eur. J. Org. Chem. 2017, DOI: 10.1002/ejoc.201700010.[3] D. Brinet, J. Kaffy, F. Oukacine, S. Glumm, S. Ongeri, M. Taverna Electrophoresis 2014, 35, 3302. [4] D. Brinet, F. Gaie-Levrel, V. Delatour, J. Kaffy, S. Ongeri, M. Taverna Talanta, 2017, 165, 84-91.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Medicinal Chemistry.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMedicinal Chemistry
  • SubjectChemistry
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Sandrine Ongeri”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels